Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2019

View Archived Issues

How starved cancers grow

Twin study identifies novel genetic mutations causing hypospadias

MolMed receives authorization to initiates phase I/II study of CAR T CD44v6 cells

Hypoxia has unexpected range of effects in antitumor therapy

Development of a novel PDX model of human prostate cancer

e-Therapeutics patents new hedgehog signaling inhibitors

Chronos Therapeutics presents orexin receptor antagonists

Selective delipidation of BCG vaccine enhances protection and enables direct pulmonary vaccination

Netherlands Translational Research Center divulges IDO1 inhibitors

XW Laboratories identifies ROS production inhibitors

Janssen Pharmaceutica describes HCV NS5B inhibitors

First patients receive treatment in phase IIa study of ModraDoc006/r in metastatic breast cancer

Trizell initiates phase III study of gene therapy TR-002 for malignant pleural mesothelioma

Eisai initiates phase III study of BAN-2401 in early Alzheimer's disease

BEECH study finds no survival benefit of adding capivasertib to paclitaxel for breast cancer

Pleckstrin-2 as a novel diagnostic biomarker in JAK2V617F-positive myeloproliferative neoplasms

Conatus reports ENCORE-NF topline results for emricasan in NASH and liver fibrosis

New PLAG1 gene variations tied to lipoblastoma

Evox secures funding to support development of exosome therapy to treat argininosuccinic aciduria

Exscientia and Celgene enter AI-led drug discovery partnership in oncology and autoimmunity

LegoChem and Takeda form ADC research collaboration and license agreement in immuno-oncology

Sihuan demonstrates proof of mechanism with CDK4/6 inhibitor birociclib in phase I

Unusual anti-inflammatory meroterpenoids isolated from the marine sponge Dysidea septosa

AZGP1 is correlated with HPV positivity in oropharyngeal squamous cell carcinoma

GATA-3 is a new biomarker of gonadotroph adenomas

Nuformix begins clinical trial of NXP-001 for CINV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...